Physician profile
Morgan E Brown
NPI 1710419726
$1,034.99
in general payments reported to CMS, 2019-2025
16 companies · $49.53 in 2025
The $49.53 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $68.92 · 2023: $233 · 2024: $133 · 2025: $49.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.04 | 2021-2024 | |
| Boston Scientific Corporation | $114.13 | 2021 | |
| Biotronik Nro, INC. | $82.33 | 2024 | Prospera |
| Collegium Pharmaceutical, INC. | $75.88 | 2021-2023 | Belbuca |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $66.03 | 2021 | |
| Averitas Pharma INC. | $65.70 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.29 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Pfizer INC. | $43.98 | 2023 | |
| Novo Nordisk INC | $38.60 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $38.31 | 2023 | Reyvow, Emgality |
| Vertex Pharmaceuticals Incorporated | $25.72 | 2025 | |
| Allergan, INC. | $19.14 | 2021 | |
| Biodelivery Sciences International, INC. | $18.34 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.